Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells (Q39400141)

11 September 2017

Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells (English)

1 reference

11 September 2017

1 reference

1 reference

Tsuyoshi Ohta

1

1 reference

11 September 2017

Masahide Ohmichi

2

1 reference

11 September 2017

Tae Shibuya

3

1 reference

11 September 2017

Toshifumi Takahashi

4

1 reference

11 September 2017

Seiji Tsutsumi

5

1 reference

11 September 2017

Kazuhiro Takahashi

6

1 reference

11 September 2017

Hirohisa Kurachi

7

1 reference

11 September 2017

language of work or name

1 reference

1 April 2012

1 reference

Cancer Biology and Therapy

11 September 2017

1 reference

11 September 2017

13

1 reference

11 September 2017

6

1 reference

11 September 2017

408-416

1 reference

Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts

11 September 2017

1 reference

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

21 January 2018

1 reference

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

21 January 2018

1 reference

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

21 January 2018

1 reference

Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line

21 January 2018

1 reference

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

21 January 2018

1 reference

Increased expression of DNA-dependent protein kinase confers resistance to adriamycin

21 January 2018

1 reference

Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).

21 January 2018

1 reference

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

21 January 2018

1 reference

DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product

21 January 2018

1 reference

Cisplatin-induced activation of the EGF receptor

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

A polymerase chain reaction-based method to detect cisplatin adducts in specific genes

21 January 2018

1 reference

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines

21 January 2018

1 reference

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

21 January 2018

1 reference

Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

21 January 2018

1 reference

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

21 January 2018

1 reference

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

21 January 2018

1 reference

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models

21 January 2018

1 reference

The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin

21 January 2018

1 reference

The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair

21 January 2018

1 reference

The pathway to signal achievement

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4161/CBT.19292

1 reference

11 September 2017

1 reference